Cesca Therapeutics 7.53M share offering priced at $1.50 Cesca Therapeutics announced the pricing of an underwritten public offering of 7.53M units, consisting of an aggregate of 7.53M shares and warrants to purchase 2.259M shares of the, at a price of $1.50 per unit. The warrants will be exercisable immediately upon issuance at an exercise price of $1.55 per share and will expire five years from the date of issuance. All of the units in the offering are being sold by Cesca. The gross proceeds to Cesca from the offering are expected to be approximately $11.3M. The offering is expected to close on or about June 18. Maxim Group is acting as sole book-running manager and H.C. Wainwright & Co. is acting as a co-manager for the offering.
Cesca Therapeutics to delay filing Form 10-Q The registrant is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, within the prescribed time period. As reported in the company’s Form 8-K dated May 12, the former independent registered public accounting firm resigned. The company needs more time to engage a successor independent registered public accounting firm and allow them time to review the management prepared Form 10-Q. No assurance can be given that the company will be able to file its quarterly report within the additional time prescribed by Rule 12b-25.